ER, We're basically on the same page. The first two rebuttals are basically in line with my overall premise because they depend on CD12 interim to uplist or get a BP deal.

We'll have to disagree on longhaulers. Just because there is a need doesn't mean we'll ever make a dime off of it.

Enrollment pace will vary. To have data in 3 months, we need to enroll another 170 in the next 60 days. I have seen nothing to indicate we can do that. If anyone else gets some EUA or approval, it could really cripple the enrollment. Let's hope it doesn't matter and the trial is halted.